drugset / Trial / NCT07657780
CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia
Phase 0
Not yet recruiting
15 enrolled
CorrectSequence Therapeutics Co., Ltd
The First Affiliated Hospital of Anhui Medical University · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, single-arm, dose-escalation IIT clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-65 years) with Severe Hypertriglyceridemia(sHTG).
Timeline
- Start
- 2026-06-15
- Primary completion
- 2028-03-15
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS-121 | CRISPR / gene editing | 0.5 mg/kg | — |
| Subject | CS-121 | CRISPR / gene editing | 0.7 mg/kg | — |
| Subject | CS-121 | CRISPR / gene editing | 1 mg/kg | — |